Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab

Inflammatory Bowel Disease

Causes of Treatment Failure In Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study

J Pediatr Gastroenterol Nutr.

Naviglio S, Lacorte D, Lucafò M, Cifù A, Favretto D, Cuzzoni E, Silvestri T, Pozzi Mucelli M, Radillo O, Decorti G, Fabris M, Bramuzzo M, Taddio A, Stocco G, Alvisi P, Ventura A, Martelossi S

doi: 10.1097/MPG.

Inflammatory Bowel Disease

Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

United European Gastroenterol J.

Guidi L, Pugliese D, Tonucci TP, Bertani L, Costa F, Privitera G, Tolusso B, Di Mario C, Albano E, Tapete G, Gremese E, Papa A, Gasbarrini A, Rapaccini GL, Armuzzi A

doi: 10.1177/2050640619873784.

Inflammatory Bowel Disease

Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring

Aliment Pharmacol Ther.

Lucidarme C, Petitcollin A, Brochard C, Siproudhis L, Dewitte M, Landemaine A, Bellissant E, Bouguen G

doi: 10.1111/apt.15046.

Inflammatory Bowel Disease

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Inflamm Bowel Dis.

Chen C, Hartzema AG, Xiao H, Wei YJ, Chaudhry N, Ewelukwa O, Glover SC, Zimmermann EM

doi: 10.1093/ibd/izz001.

Inflammatory Bowel Disease

Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-based vs Trough Concentration-based Dosing of Infliximab

Clin Gastroenterol Hepatol.

Pouillon L, Ferrante M, Van Assche G, Rutgeerts P, Noman M, Sabino J, Vande Casteele N, Gils A, Vermeire S

doi: 10.1016/

Inflammatory Bowel Disease

Treatment of Inflammatory Bowel Disease in the Older Patient

Inflamm Bowel Dis.

Dorreen A, Heisler C, Jones J

doi: 10.1093/ibd/izy023.

Inflammatory Bowel Disease

Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland

Eur J Gastroenterol Hepatol.

Guilcher K, Fournier N, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A; Swiss IBD Cohort Study

doi: 10.1097/

Inflammatory Bowel Disease

The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy

Inflamm Bowel Dis.

Lin SC, Goldowsky A, Papamichael K, Cheifetz AS

doi: 10.1093/ibd/izy376.

Inflammatory Bowel Disease

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months

Clin Gastroenterol Hepatol.

Williet N, Boschetti G, Fovet M, Di Bernado T, Claudez P, Del Tedesco E, Jarlot C, Rinaldi L, Berger A, Phelip JM, Flourie B, Nancey S, Paul S, Roblin X

doi: 10.1016/j.cgh.2016.11.023.

Related content

Causes of Treatment Failure In Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study

Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-based vs Trough Concentration-based Dosing of Infliximab

Treatment of Inflammatory Bowel Disease in the Older Patient

Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland

The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months